$Genprex (GNPX.US)$
Genprex's announcement represents positive early-stage validation for its lead candidate Reqorsa in a tough-to-treat subset of non-small cell lung cancer. The preclinical data specifically addresses KRASG12C mutant NSCLC with acquired resistance to sotorasib (Lumakras), highlighting a significant unmet need in lung cancer treatment.
The data demonstrates Reqorsa's multifaceted mechanism as a TUSC2 gene therapy - inhibiting critical signaling pathways (MAPK and...

$Genprex (GNPX.US)$
Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer in Latest Study

$Genprex (GNPX.US)$
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Wednesday, 26th March at 8:15 am
Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer
AUSTIN, Texas, March 26, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changi...

$Predictive Oncology (POAI.US)$ took profit  $Genprex (GNPX.US)$ eyeing on this too

$Genprex (GNPX.US)$ 2

$Genprex (GNPX.US)$
Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients

$Genprex (GNPX.US)$ Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
PR Newswire· 4 mins ago
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes
AUSTIN, Texas, March 25, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabete...

$Genprex (GNPX.US)$ 💩